ROCKVILLE, Md., March 21 (UPI) -- U.S. firm Emergent BioSolutions said Wednesday it has filed for U.S. approval to test a new treatment for anthrax.
The company said it is seeking approval from the Food and Drug Administration for Anthrax Immune Globulin, a treatment for patients with symptoms of anthrax disease.
With the FDA's go-ahead, expected in about one month, Emergent said it can begin a one-year clinical trial involving 105 healthy volunteers.
The study "is a significant step as we continue to expand our anthrax biodefense product franchise, which includes BioThrax (Anthrax Vaccine Adsorbed), the only FDA-licensed vaccine against anthrax infection, as well as development programs focused on improvements to BioThrax and an enhanced anthrax vaccine," said Fuad El-Hibri, the firm's chairman and CEO.
